The first human trial for CanSino’s non-replicating recombinant adenovirus type-5 vectored COVID-19 vaccine was tested on healthy adults in Wuhan, Hubei Province, China. The study assessed the safety, tolerability, and immunogenicity of the COVID-19 vaccine 28 days post-vaccination. 

First human trial of the adenovirus type-5 vectored COVID-19 vaccine

The second human trial for Ad5-nCoV is being performed in Wuhan, China with primary outcomes in determining specific and neutralizing antibody responses and adverse reaction occurrences in subjects to determine the efficacy and safety of the vaccine. Another purpose of this trial was to further narrow down an appropriate dose for the vaccine candidate. 

Second human trial of the Ad5-nCoV vaccine

University of Michigan - Ann Arbor

Rutgers University

The vaccine is composed of an adenovirus vector that codes for the S protein. Phase 1 trial of the vaccine over three dose groups using a dose-escalation, sample. Ad5 had shown tolerable and immunogenic results 4 weeks after vaccinations.

Learn Before

Related

Learn After